HBsAg

Applied sciences
Health sciences
Hepatology
Liver disease

About
Privacy
Disclaimer

Graph Chatbot

Related publications (4)

Induction of a strong and long-lasting neutralizing immune response by dPreS1-TLR2 agonist nanovaccine against hepatitis B virus

Myriam Isabelle Lamrayah

Hepatitis B virus remains a major medical burden with more than 250 million chronically infected patients worldwide and 900,000 deaths each year, due to the disease progression towards severe complications (cirrhosis, hepatocellular carcinoma). Despite the ...

ELSEVIER2023

Human genomics of acute liver failure due to hepatitis B virus infection: An exome sequencing study in liver transplant recipients

Jacques Fellay, Christian Hammer, Nimisha Chaturvedi, Petar Scepanovic, Samira Asgari

Acute liver failure (ALF) or fulminant hepatitis is a rare, yet severe outcome of infection with hepatitis B virus (HBV) that carries a high mortality rate. The occurrence of a life-threatening condition upon infection with a prevalent virus in individuals ...

2019

APOBEC3-independent interferon-induced viral clearance in hepatitis B virus transgenic mice

Didier Trono, Priscilla Turelli, Bastien Mangeat, Stéphanie Jost, Sonia Verp

Interferon (IFN) has been part of the standard treatment of chronic hepatitis B infection for more than 2 decades, yet the mechanism of action of this antiviral remains poorly understood. It was recently observed that members of the human APOBEC family of ...

American Society for Microbiology2008

Polynucleotide cytidine deaminases, innate immunity and hepatitis B infection

Stéphanie Jost

More than 350 millions individuals worldwide suffer from chronic hepatitis B virus (HBV) infection, a condition that evolves towards liver insufficiency and hepatocellular carcinoma in approximately 15 to 40 percent of cases. Yet the majority of de novo HB ...

EPFL2007

Page 1 of 1